Adis Journals
Browse
Graphical Abstract.pdf (157.17 kB)
Download file

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and after the COVID-19 Era

Download (157.17 kB)
media
posted on 2022-05-06, 08:19 authored by Stefan Schreiber, Shomron Ben-Horin, Rieke Alten, Rene Westhovens, Laurent Peyrin-Biroulet, Silvio Danese, Toshifumi Hibi, Ken Takeuchi, Fernando Magro, Yoorim An, Dong-Hyeon Kim, SangWook Yoon, Walter Reinisch

Article full text


The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

© The authors, CC-BY-NC 2022.

History

Usage metrics

    Advances in TherapyAdvances in Therapy

    Categories

    Keywords

    Biobetterscoronavirus disease 2019 (COVID-19)CT-P13 SCinflammatory bowel diseaseinnovative biologicsreal-world evidencerheumatic diseasessubcutaneous infliximabtelemedicine

    Licence

    CC BY-NC 4.0

    Exports